Integrative care guided by biological aging markers for unexplained female infertility
An Interventional Study Evaluating Telomere and Biological Aging Hallmarks Profiling to Guide an Integrative Traditional Chinese and Conventional Medicine Approach in Women With Post-Treatment Unexplained Infertility
This trial tests whether measuring telomeres and other biological aging markers can guide a personalized integrative treatment to help women aged 25–42 with persistent unexplained infertility improve their chances of pregnancy.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 15 (estimated) |
| Ages | 25 Years to 42 Years |
| Sex | Female |
| Sponsor | BEYOND GENOMiX SA, AG, Ltd Industry-sponsored |
| Locations | 1 site (Neuchâtel) |
| Trial ID | NCT07404969 on ClinicalTrials.gov |
What this trial studies
Women aged 25–42 with persistent post‑treatment unexplained infertility undergo baseline reproductive evaluation and telomere and other biological aging biomarker profiling. Based on these profiles, participants receive a personalized integrative intervention that includes botanical and nutraceutical therapies prior to attempts at natural conception or continuation of assisted reproductive technologies (ART). The trial tracks clinical pregnancy and related reproductive outcomes to compare the biomarker-guided integrative approach with usual care pathways. The protocol also aims to define a biological aging phenotype associated with reproductive failure and determine whether targeting cellular aging processes improves outcomes.
Who should consider this trial
Good fit: Women aged 25–42 who continue to experience infertility despite appropriate management of identifiable reproductive conditions and repeated IUI or IVF attempts are ideal candidates.
Not a fit: Women with a clearly identified and treatable cause of infertility or those unwilling to undergo biomarker testing or botanical/nutraceutical interventions are less likely to benefit.
Why it matters
Potential benefit: If successful, this approach could increase pregnancy rates by tailoring treatments to underlying cellular aging processes rather than only structural or hormonal factors.
How similar studies have performed: Emerging research links telomere and mitochondrial dysfunction to reproductive aging, but using biomarker-guided integrative treatments for infertility remains largely experimental.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Biological female participants aged 25 to 42 years. * Diagnosis of infertility defined as failure to conceive after at least 12 months of unprotected intercourse and/or repeated failure of assisted reproductive technologies (ART), including intrauterine insemination (IUI) and/or in vitro fertilization (IVF). * History of post-treatment unexplained or functionally idiopathic infertility, defined as persistent infertility despite adequate correction or management of identifiable reproductive conditions (e.g., endometriosis, polycystic ovary syndrome, hormonal imbalance, uterine factors). * Eligibility for natural conception attempts and/or assisted reproductive technologies according to routine clinical practice. * Willingness to undergo biological aging biomarker profiling, including leukocyte telomere analysis. * Ability and willingness to comply with study procedures, including the preconception integrative intervention and follow-up assessments. * Provision of written informed consent prior to participation. Exclusion Criteria: * Current pregnancy or breastfeeding at the time of enrollment. * Known chromosomal abnormalities or genetic conditions directly impairing fertility (e.g., Turner syndrome). * Untreated severe male factor infertility precluding conception by natural or standard ART methods. * Active malignancy or history of cancer requiring systemic treatment within the past 5 years. * Severe systemic disease or medical condition contraindicating pregnancy or participation in ART (as determined by the treating physician). * Use of investigational drugs or participation in another interventional clinical trial that could interfere with the study outcomes. * Known hypersensitivity or contraindication to components of the integrative intervention, as determined by clinical assessment. * Any condition which, in the opinion of the investigator, would interfere with safe participation or interpretation of study results.
Where this trial is running
Neuchâtel
- BEYOND GENOMiX Research and Coordination Center — Neuchâtel, Switzerland (Recruiting)
Study contacts
- Study coordinator: M. Merarchi
- Email: pm@beyondgenomix.com
- Phone: +4132 552 60 00
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.